Tirzepatide
Dual GIP/GLP-1 Receptor Agonist
Dosage
10mg
Unit Size
1 Vial
// Add to Cart
10mg
$100.00
30 in stock
What is Tirzepatide?
Tirzepatide is a novel synthetic peptide that acts as a dual agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. Originally developed for metabolic research, it has been extensively studied for its effects on glucose regulation, body composition, and energy homeostasis. Its dual-receptor mechanism distinguishes it from single GLP-1 agonists, producing synergistic effects on insulin sensitivity and appetite regulation.
Dual
GIP + GLP-1 Agonist
GIP/GLP
Receptor Targets
High
Metabolic Activity
Key Benefits
Weight & Body Composition
Studied for significant reductions in body weight through appetite suppression and improved energy utilization.
Glucose Regulation
Dual receptor activation enhances glucose-dependent insulin secretion and reduces glucagon levels, supporting healthy glycemic research.
Energy Homeostasis
Influences central energy balance pathways, increasing metabolic rate and reducing caloric intake in research models.
Lean Mass Preservation
Research suggests tirzepatide may preserve lean muscle mass during weight reduction phases, distinguishing it from other metabolic peptides.
Cardiovascular Markers
Investigated for favorable effects on lipid profiles, blood pressure, and inflammatory cardiovascular markers.
Insulin Sensitivity
GIP receptor activation improves insulin sensitivity in peripheral tissues, contributing to comprehensive metabolic support in research.
How It Works
GLP-1 Receptor Activation
Binds GLP-1 receptors in the pancreas and brain, stimulating glucose-dependent insulin secretion and reducing appetite signaling.
GIP Receptor Co-Activation
Simultaneously activates GIP receptors, enhancing the insulinotropic response and improving peripheral insulin sensitivity beyond GLP-1 agonism alone.
Central Appetite Modulation
Acts on hypothalamic pathways to reduce hunger signals and increase satiety, supporting reduced caloric intake in research subjects.
Adipose Tissue Regulation
GIP receptor activity in adipose tissue influences fat storage and mobilization, contributing to improved body composition outcomes observed in studies.
Common Protocol (Research Reference)
2.5–15mg
Dose per injection
1×/week
Frequency (subcutaneous)
12–72 wks
Typical research cycle
Research Use Notice
Tirzepatide is a research peptide not approved by the FDA for human use. This information is for educational purposes only. Always consult a qualified healthcare professional before considering any peptide protocol.